Wedbush Weighs in on Xencor’s Q2 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR) – Equities research analysts at Wedbush cut their Q2 2025 earnings per share estimates for shares of Xencor in a report released on Wednesday, May 7th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn ($0.78) per share for the quarter, down from their prior estimate of ($0.60). Wedbush has a “Outperform” rating and a $31.00 price target on the stock. The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. Wedbush also issued estimates for Xencor’s Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.03) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.80) EPS, FY2026 earnings at ($3.20) EPS, FY2027 earnings at ($3.39) EPS, FY2028 earnings at ($4.29) EPS and FY2029 earnings at ($5.95) EPS.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). The firm had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm’s quarterly revenue was up 104.6% compared to the same quarter last year. During the same period last year, the company posted ($1.11) earnings per share.

A number of other brokerages have also commented on XNCR. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Barclays decreased their price objective on Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a report on Thursday, May 8th. William Blair assumed coverage on Xencor in a report on Monday, April 21st. They set an “outperform” rating for the company. Finally, Wells Fargo & Company decreased their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.50.

Xencor Stock Performance

Shares of XNCR opened at $8.11 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The stock has a 50 day moving average price of $10.63 and a two-hundred day moving average price of $17.52. The firm has a market capitalization of $577.04 million, a P/E ratio of -2.53 and a beta of 0.99. Xencor has a 52 week low of $7.16 and a 52 week high of $27.24.

Hedge Funds Weigh In On Xencor

Institutional investors have recently modified their holdings of the business. Sterling Capital Management LLC grew its holdings in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Xencor in the fourth quarter valued at approximately $34,000. CWM LLC lifted its stake in Xencor by 195.5% in the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 2,231 shares during the last quarter. GAMMA Investing LLC lifted its stake in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 508 shares during the last quarter. Finally, KBC Group NV lifted its stake in Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 813 shares during the last quarter.

Insider Activity

In other news, EVP Nancy Valente sold 4,616 shares of the company’s stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the transaction, the executive vice president now directly owns 49,169 shares of the company’s stock, valued at $542,334.07. This represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.76% of the stock is currently owned by corporate insiders.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.